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Background: The dopaminergic system is involved in a wide range of cognitive functions
including motor control, reward, memory, attention, problem-solving and learning. This
has stimulated interest in investigating the potential of dopaminergic drugs as cognitive
enhancers in aphasic patients.
Aim: To discuss the evidence for the use of dopaminergic agents in patients with aphasia.
Levodopa (L-dopa) and the dopamine agonist bromocriptine are the two drugs that have
been trialled to date. We discuss, in some detail, the 15 studies that have been published
on this topic from the first case report in 1988 to the present (2012), and assess the evi-
dence from each.
Main contribution: In addition to summarising the effectiveness of the drugs that have
been tried, we examine the possible cognitive mechanisms by which dopaminergic
drugs may act on language function and aphasia recovery. Given the wide range of
dopaminergic drugs, it is surprising that such a narrow range has been trialled in aphasic
patients. Important lessons are to be learned from published studies and we discuss opti-
mal trial designs to help guide future work.
Conclusions: The evidence for the efficacy of dopaminergic agents in aphasia therapy is
mixed. Further trials with better tolerated agents are required. Optimal trial designs with
appropriate control groups or blocks should be used. The mechanism of action is unclear,
but at the cognitive level the evidence points towards either (re)learning of word-forms or
their improved retrieval.
Keywords: Dopamine; Aphasia; Review; L-dopa; Bromocriptine.
Levodopa (L-dopa) and the dopamine agonist bromocriptine are the two main drugs
that have been trialled to date in patients with acquired aphasia. These studies were
prompted by the observation that some Parkinsonian patients noted improved speech
function following L-dopa therapy (Quaglieri & Celesia, 1977). Subsequent studies in
patients with Parkinson’s disease have shown that dopamine therapy can modulate
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the motoric aspects of speech: articulation and phonation, see (Goberman & Coelho,
2002) for a review of this literature; as well as the more linguistic aspects, verbal fluency
(Gotham, Brown, & Marsden, 1988) and even sentence comprehension (Grossman
et al., 2001). In post-stroke aphasia, the first reported use of dopaminergic therapy
was bromocriptine used in a 62-year-old patient with a severe transcortical motor
aphasia following a left frontal intracerebral haemorrhage 3.5 years prior to therapy.
The bromocriptine caused a small improvement in his confrontation naming (5–10%)
with a more marked improvement of the fluency of his spontaneous speech, and
pauses between utterances were reduced by 24% (Albert, Bachman, Morgan, & Helm-
Estabrooks, 1988). Single-case studies are often difficult to interpret, but if more than
one period of “off–drug” is included, this helps. In this case, the patient’s language
function returned to baseline after cessation of therapy.
Before examining the rest of the literature, we will provide a quick pharmacolog-
ical and anatomical resume of the dopaminergic system in humans. Dopamine is a
monoamine neurotransmitter whose function was first characterised in 1958 (Benes,
2001). It is synthesised from L-3,4-dihydroxyphenylalanine (L-dopa), 95% of which is
turned into dopamine by the action of the enzyme dopa-decarboxylase. The remain-
ing 5% is then converted to noradrenaline and acts on adrenergic receptors. Dopamine
acts on five subtypes of the dopamine receptor; however, these receptors fall into two
main groups based on morphological grounds: D2-like (D2–D4: primarily located
in the striatal neurons) and D1-like (D1 and D5: primarily located in the cortical
neurons) (Civelli, Bunzow, & Grandy, 1993). Endogenous dopamine is mainly pro-
duced by two paired, midbrain nuclei which are situated close to each other: the
ventral tegmental area (VTA) and substantia nigra (SN). Both project to different
parts of the striatum and indirectly affect the cortical neurons via cortico-basal gan-
glia circuits, although the VTA also projects directly to prefrontal cortex (Figure 1(a)).
A widespread subpopulation of cortical neurons also have dopamine receptors, so
exogenous dopamine, particularly the receptor agonists and antagonists, have two
main routes to affect the behaviour; either directly, or through existing cortico-basal
ganglia circuits. Dopamine has been implicated in modulating a whole range of
cognitive functions: motor control, reward, memory, attention, problem-solving and
learning (Alexander, DeLong, & Strick, 1986) and could potentially affect language
recovery through any or all of these.
The relative affinity of each dopamine agonist for each receptor subtype provides
both its therapeutic effect and unwanted side effects. For example, the motor improve-
ment seen in Parkinson’s patients is attributed to the stimulation of D2 receptors in
the caudate and putamen, as are the unwanted end of dose deterioration and dyski-
nesias (Kvernmo, Hartter, & Burger, 2006). Perhaps surprisingly, the only dopamine
agonist trialled in aphasic patients to date is bromocriptine. Bromocriptine is primarily
a D2 receptor agonist with some D1 receptor antagonist properties (Kvernmo et al.,
2006).
TRIAL EVIDENCE
Interest in dopaminergic effects on language recovery stemmed from the single-case
study by Albert et al. (1988) and discussed above. The better trials have tended to be
those with larger numbers and included a placebo-controlled arm. Without a placebo
arm, patients always know when they are on the active drug so placebo effects can
muddy the picture. Even with a placebo, not all trials blind the patient to this infor-
mation (open-label trials). Some form of control arm or block is always preferable
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Figure 1. (a) The two main dopaminergic nuclei are close to each other in the midbrain with the substantia
nigra projecting to the striatum and the ventral tegmental area projecting to both the nucleus accumbens
(part of the ventral striatum) and the frontal cortex. (b) The nigrostriatal pathway affects cortical function
indirectly through a series of cortico-basal ganglia circuits. The substantia nigra (pars compacta) projects
to the striatum (caudate and putamen in blue). The main output of the striatum is to the globus pallidus
(green) and thence to the thalamus (pink) and cortex (green arrows). The cortex feeds back to the striatum
(green arrows) to close the loop on the cortico-basal ganglia circuits. There are also dopaminergic receptors
on many cortical neurons (not shown). http://en.wikipedia.org/wiki/File:Basal_ganglia_circuits.svg. Mikael
Häggström, based on images by Andrew Gillies.
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because most patients are on an upward recovery curve. Even though “spontaneous”
recovery slows three months post infarct (Lazar et al., 2010; Lomas & Kertesz,
1978), therapy-driven improvements in aphasia are reported in the chronic phase,
even decades after the stroke occurred (Moss & Nicholas, 2006; Price, Seghier, &
Leff, 2010). All but three of the trials reported here were performed in the chronic
phase (defined as >6 months post-stroke); there is good evidence that treatments
aimed at improving language outcomes are effective in this latter time period (Allen,
Mehta, McClure, & Teasell, 2012). The 15 studies in aphasic patients (the vast major-
ity with stroke) covered by this review are summarised in Table 1. Relevant studies
were found by searching PubMED and Google Scholar using the following terms:
aphasia, anomia, bromocriptine, dopaminergic, drug therapy, L-dopa, levodopa and
rehabilitation. Two single cases, both reported in books, were highlighted by one of
the referees. We will discuss them in chronological order.
Bromocriptine has been the drug of choice in 13 of the 15 studies. In Parkinson’s
disease, a dose range of 10–30 mg is usual, although bromocriptine has some-
what fallen out of favour with movement disorder specialists who prefer the newer
dopamine agonists such as pramipexole and ropinirole.While bromocriptine is consid-
ered to be an effective treatment for Parkinson’s disease, movement disorder specialists
generally avoid all ergot-derived dopamine agonists because of the risks of lung fibro-
sis and heart valvulopathies (Dr Prasad Korlipara, Personal communication, 8 March
2013; Andersohn & Garbe, 2009). In order to minimise the occurrence of side effects,
most studies employed an escalating dose regime up to 10 mg/day. Most titrated to
between 10–30 mg but one group preferred to escalate to 60 mg. In the latter of their
two studies, four of the seven patients taking part (57%) suffered side effects of nausea,
dystonic movements or a lack of energy in the bromocriptine block (Sabe, Salvarezza,
Garcia Cuerva, Leiguarda, & Starkstein, 1995). Another study with 11 patients
titrated to 30 mg/day had a 63% incidence of side effects (Bragoni et al., 2000).
In 1991, MacLennan reported a case similar to the Albert one, although they used
an AB and not an ABA design, which makes it difficult to interpret. Like the Albert
case, there was no statistical treatment of the behavioural data, but there were two
methodological improvements: a placebo was used with the subject blinded to the
order of placebo/bromocriptine therapy, and a simple motor reaction time test was
used to gauge any motoric effects of bromocriptine. There was no convincing effect
of bromocriptine on motoric reaction time, naming or word fluency. The patient pro-
duced about 50% more words on a test of spoken picture description, with this effect
continuing into the drug withdrawal phase. It is difficult to interpret this as the drug
effect could be confounded by practice effects. The authors themselves concluded that
the study was negative although, interestingly, the patient did not agree (MacLennan,
Morley, & Brookshire, 1991).
In 1992, Gupta and Mlcoch (1992) went one better than the papers by Albert and
MacLennan and reported a positive effect of bromocriptine in two aphasic patients
with nonfluent aphasia in the chronic phase. Using an AB design (but no placebo
block), both were started on bromocriptine and escalated from 10 mg to 30 mg/day.
The main outcome measure was mean length of utterance, derived from an analysis
of spoken picture description. The first patient showed some improvement in fluency
at 10 mg and marked improvement at 30 mg, but it is difficult to rule out a simple
time-effect (they perhaps should have tested him with an ABA design like Albert).
The second patient’s results were more interesting; he improved at 10 mg, got worse
at 30 mg and improved again at 10 mg suggesting that, if the effect was due to the
DOPAMINERGIC THERAPY IN APHASIA 159
TA
B
LE
1
S
u
m
m
ar
y
o
f
th
e
15
st
u
d
ie
s
co
ve
re
d
b
y
th
is
re
vi
ew
T
it
le
,1
st
au
th
or
,y
ea
r
T
ri
al
ty
pe
D
ru
g
an
d
do
se
N
o.
P
ts
A
ph
as
ia
ty
pe
an
d
ch
ro
ni
ci
ty
M
ai
n
ou
tc
om
es
,c
om
m
en
ts
P
ha
rm
ac
ot
he
ra
py
fo
r
ap
ha
si
a.
A
lb
er
t
(1
98
8)
.
Si
ng
le
ca
se
,n
o
pl
ac
eb
o,
A
B
A
de
si
gn
.
B
ro
m
oc
ri
pt
in
e,
15
th
en
30
m
g
1
T
ra
ns
co
rt
ic
al
m
ot
or
ap
ha
si
a.
3.
5
ye
ar
s
po
st
-s
tr
ok
e.
P
ai
re
d
w
it
h
th
er
ap
y.
R
ed
uc
ed
he
si
ta
nc
y,
de
cr
ea
se
d
pa
ra
ph
ra
si
as
an
d
in
cr
ea
se
d
na
m
in
g
ab
ili
ty
.R
et
ur
n
to
ba
se
lin
e
af
te
r
ce
ss
at
io
n
of
th
er
ap
y.
T
he
ef
fe
ct
s
of
br
om
oc
ri
pt
in
e
on
sp
ee
ch
an
d
la
ng
ua
ge
fu
nc
ti
on
in
a
m
an
w
it
h
tr
an
sc
or
ti
ca
lm
ot
or
ap
ha
si
a.
M
ac
L
en
na
n,
19
90
.
Si
ng
le
ca
se
,
pl
ac
eb
o-
co
nt
ro
lle
d,
si
ng
le
bl
in
de
d,
A
B
de
si
gn
.
B
ro
m
oc
ri
pt
in
e
2.
5
m
g
in
cr
ea
se
d
to
15
m
g
1
T
ra
ns
co
rt
ic
al
m
ot
or
ap
ha
si
a.
4
ye
ar
s
po
st
-s
tr
ok
e.
A
n
in
cr
ea
se
in
no
.w
or
ds
an
d
co
rr
ec
t
in
fo
rm
at
io
n
un
it
s,
bu
t
no
st
at
is
ti
ca
la
na
ly
si
s
m
ad
e.
C
ha
ng
es
co
ul
d
be
du
e
to
pr
ac
ti
ce
or
ca
rr
y-
ov
er
ef
fe
ct
s.
B
ro
m
oc
ri
pt
in
e
tr
ea
tm
en
t
of
no
n-
flu
en
t
ap
ha
si
a.
G
up
ta
(1
99
2)
.
Tw
o
ca
se
s,
no
pl
ac
eb
o,
A
B
de
si
gn
.
B
ro
m
oc
ri
pt
in
e,
es
ca
la
te
d
do
se
:
10
m
g,
30
m
g
2
1
=
B
ro
ca
’s
ap
ha
si
a;
1
=
tr
an
sc
or
ti
ca
lm
ot
or
ap
ha
si
a.
18
m
on
th
s
an
d
10
ye
ar
s
po
st
-s
tr
ok
e.
D
ru
g
al
on
e,
no
t
pa
ir
ed
w
it
h
th
er
ap
y.
F
lu
en
cy
of
sp
ee
ch
im
pr
ov
ed
in
bo
th
.I
n
th
e
se
co
nd
ca
se
w
or
se
on
30
m
g
an
d
im
pr
ov
ed
w
he
n
do
se
de
es
ca
la
te
d
to
10
m
g.
A
n
op
en
la
be
lt
ri
al
of
br
om
oc
ri
pt
in
e
in
no
n-
flu
en
t
ap
ha
si
a.
Sa
be
(1
99
2)
.
N
o
pl
ac
eb
o,
A
B
A
ra
m
p-
up
,
ra
m
p-
do
w
n
de
si
gn
.
B
ro
m
oc
ri
pt
in
e,
up
to
60
m
g/
da
y
7
4
=
tr
an
sc
or
ti
ca
lm
ot
or
ap
ha
si
a;
2
=
B
ro
ca
’s
ap
ha
si
a;
1
=
gl
ob
al
ap
ha
si
a.
>
1
ye
ar
po
st
-s
tr
ok
e.
P
ai
re
d
w
it
h
th
er
ap
y.
A
n
im
pr
ov
em
en
t
se
en
in
th
os
e
w
ho
w
er
e
m
od
er
at
el
y
af
fe
ct
ed
(4
:3
)
w
it
h
in
cr
ea
se
d
w
or
d
fin
di
ng
an
d
ve
rb
al
flu
en
cy
in
cr
ea
si
ng
on
dr
ug
co
m
pa
re
d
w
it
h
ba
se
lin
e
an
d
th
en
de
cr
ea
si
ng
as
th
e
dr
ug
w
as
w
it
hd
ra
w
n.
A
ra
nd
om
is
ed
,d
ou
bl
e
bl
in
d,
pl
ac
eb
o
co
nt
ro
lle
d
st
ud
y
of
br
om
oc
ri
pt
in
e
in
no
n-
flu
en
t
ap
ha
si
a.
Sa
be
(1
99
5)
.
R
an
do
m
is
ed
∗ ,
do
ub
le
-b
lin
d,
pl
ac
eb
o-
co
nt
ro
lle
d,
cr
os
so
ve
r
de
si
gn
.
B
ro
m
oc
ri
pt
in
e,
up
to
60
m
g/
da
y
7
2
=
B
ro
ca
’s
ap
ha
si
a;
3
=
tr
an
sc
or
ti
ca
lm
ot
or
ap
ha
si
a;
2
=
an
om
ic
ap
ha
si
a.
>
1
ye
ar
po
st
-s
tr
ok
e.
N
o
be
ne
fit
m
ea
su
re
d
ov
er
pl
ac
eb
o
in
he
si
ta
nc
y,
ve
rb
al
na
m
in
g,
ve
rb
al
flu
en
cy
,c
on
te
nt
w
or
ds
or
co
nt
en
t
un
it
s.
H
ig
h
ra
te
of
si
de
ef
fe
ct
s
in
th
er
ap
y
bl
oc
k
(5
7%
)
co
m
pa
re
d
w
it
h
co
nt
ro
l
bl
oc
k
(0
%
).
(C
on
ti
nu
ed
)
160 GILL AND LEFF
TA
B
LE
1
(C
o
n
ti
n
u
ed
)
T
it
le
,1
st
au
th
or
,y
ea
r
T
ri
al
ty
pe
D
ru
g
an
d
do
se
N
o.
P
ts
A
ph
as
ia
ty
pe
an
d
ch
ro
ni
ci
ty
M
ai
n
ou
tc
om
es
,c
om
m
en
ts
B
ro
m
oc
ri
pt
in
e
tr
ea
tm
en
t
of
no
n-
flu
en
t
ap
ha
si
a.
G
up
ta
(1
99
5)
.
D
ou
bl
e-
bl
in
d,
pl
ac
eb
o-
co
nt
ro
lle
d,
cr
os
so
ve
r
de
si
gn
.
B
ro
m
oc
ri
pt
in
e,
up
to
15
m
g/
da
y
20
7
=
tr
an
sc
or
ti
ca
lm
ot
or
ap
ha
si
a;
4
=
B
ro
ca
’s
ap
ha
si
a;
9
=
“m
ix
ed
an
te
ri
or
ap
ha
si
a”
.
>
1
ye
ar
po
st
-s
tr
ok
e.
D
ru
g
al
on
e,
no
t
pa
ir
ed
w
it
h
th
er
ap
y
(t
he
ra
py
w
as
no
t
al
lo
w
ed
du
ri
ng
th
e
tr
ia
l)
.
N
o
im
pr
ov
em
en
t
in
sp
ee
ch
flu
en
cy
,l
an
gu
ag
e
co
nt
en
t,
ov
er
al
la
ph
as
ia
se
ve
ri
ty
or
no
n-
ve
rb
al
co
gn
it
iv
e
pr
ob
le
m
s.
B
ro
m
oc
ri
pt
in
e
is
in
ef
fe
ct
iv
e
in
th
e
tr
ea
tm
en
t
of
ch
ro
ni
c
no
n-
flu
en
t
ap
ha
si
a.
O
ze
re
n
(1
99
5)
.
N
o
pl
ac
eb
o,
A
B
de
si
gn
.
B
ro
m
oc
ri
pt
in
e,
10
–2
5
m
g/
da
y
4
2
=
B
ro
ca
’s
ap
ha
si
a;
1
=
tr
an
sc
or
ti
ca
lm
ot
or
ap
ha
si
a;
1
=
gl
ob
al
.2
4
to
35
m
on
th
s
po
st
-s
tr
ok
e.
N
o
si
gn
ifi
ca
nt
im
pr
ov
em
en
ts
on
“a
ph
as
ia
te
st
s”
(a
sp
ee
ch
sa
m
pl
e
ra
te
d
on
an
or
di
na
l
sc
al
e
of
th
re
e
po
in
ts
).
O
ut
co
m
e
m
ea
su
re
al
m
os
t
ce
rt
ai
nl
y
no
t
se
ns
it
iv
e
to
ch
an
ge
.
T
ra
ns
co
rt
ic
al
m
ot
or
ap
ha
si
a.
B
er
th
ie
r
(1
99
9)
.
Si
ng
le
ca
se
,n
o
pl
ac
eb
o,
A
B
de
si
gn
.
B
ro
m
oc
ri
pt
in
e,
ti
tr
at
ed
to
20
m
g/
da
y
1
T
ra
ns
co
rt
ic
al
m
ot
or
ap
ha
si
a.
B
ila
te
ra
l
st
ri
at
oc
ap
su
la
r
st
ro
ke
s
(1
2
an
d
5
m
on
th
s
pr
io
r
to
st
ud
y)
w
it
h
P
ar
ki
ns
on
ia
n
fe
at
ur
es
.
P
at
ie
nt
im
pr
ov
ed
m
ar
ke
dl
y
on
sp
ok
en
pi
ct
ur
e
de
sc
ri
pt
io
n
an
d
ap
ha
si
a
qu
ot
ie
nt
of
th
e
W
A
B
.
M
ix
tu
re
of
im
pr
ov
em
en
ts
in
P
ar
ki
ns
on
ia
n
(m
ot
or
ic
)
an
d
w
or
d
fin
di
ng
as
pe
ct
s
of
sp
ee
ch
.
A
n
op
en
la
be
lt
ri
al
of
br
om
oc
ri
pt
in
e
in
no
n-
flu
en
t
ap
ha
si
a:
a
qu
al
it
at
iv
e
an
al
ys
is
of
w
or
d
st
or
ag
e
an
d
re
tr
ie
va
l.
G
ol
d
(2
00
0)
.
N
o
pl
ac
eb
o,
A
B
B
A
de
si
gn
.
B
ro
m
oc
ri
pt
in
e,
15
m
g/
da
y
4
2
=
B
ro
ca
’s
ap
ha
si
a;
2
=
tr
an
sc
or
ti
ca
lm
ot
or
ap
ha
si
a.
7
to
78
m
on
th
s
po
st
-s
tr
ok
e.
D
ru
g
al
on
e,
no
t
pa
ir
ed
w
it
h
SA
LT
.A
si
gn
ifi
ca
nt
im
pr
ov
em
en
t
in
w
or
d
re
tr
ie
va
l
fo
r
al
lf
ou
r
on
br
om
oc
ri
pt
in
e
th
er
ap
y
w
it
h
th
re
e
ex
pe
ri
en
ci
ng
de
cr
ea
se
s
af
te
r
w
it
hd
ra
w
al
.
(C
on
ti
nu
ed
)
DOPAMINERGIC THERAPY IN APHASIA 161
TA
B
LE
1
(C
o
n
ti
n
u
ed
)
T
it
le
,1
st
au
th
or
,y
ea
r
T
ri
al
ty
pe
D
ru
g
an
d
do
se
N
o.
P
ts
A
ph
as
ia
ty
pe
an
d
ch
ro
ni
ci
ty
M
ai
n
ou
tc
om
es
,c
om
m
en
ts
B
ro
m
oc
ri
pt
in
e
an
d
sp
ee
ch
th
er
ap
y
in
no
nfl
ue
nt
ch
ro
ni
c
ap
ha
si
a
af
te
r
st
ro
ke
.
B
ra
go
ni
(2
00
0)
.
D
ou
bl
e-
bl
in
d
pl
ac
eb
o-
co
nt
ro
lle
d,
bu
t
no
t
ra
nd
om
is
ed
(p
la
ce
bo
1s
t
bl
oc
k;
br
om
oc
ri
pt
in
e
2n
d
bl
oc
k)
.
B
ro
m
oc
ri
pt
in
e,
30
m
g/
da
y
11
(5
#
)
9
=
B
ro
ca
’s
ap
ha
si
a;
2
=
gl
ob
al
ap
ha
si
a.
6
to
96
m
on
th
s
po
st
-s
tr
ok
e.
Im
pr
ov
ed
di
ct
at
io
n,
re
ad
in
g-
co
m
pr
eh
en
si
on
,
re
pe
ti
ti
on
an
d
ve
rb
al
la
te
nc
y
bu
t
on
ly
5/
11
co
m
pl
et
ed
th
e
st
ud
y.
Su
pp
os
ed
ly
do
ub
le
-b
lin
d
bu
t
hi
gh
le
ve
lo
f
si
de
ef
fe
ct
s.
P
la
ce
bo
-c
on
tr
ol
le
d
bu
t
no
t
bl
oc
k-
ra
nd
om
is
ed
.
E
ff
ec
ts
of
br
om
oc
ri
pt
in
e
in
a
pa
ti
en
t
w
it
h
cr
os
se
d
no
n-
flu
en
t
ap
ha
si
a:
a
ca
se
re
po
rt
.R
ay
m
er
(2
00
1)
.
Si
ng
le
ca
se
,n
o
pl
ac
eb
o,
A
B
A
B
A
de
si
gn
.
B
ro
m
oc
ri
pt
in
e,
es
ca
la
ti
ng
do
se
up
to
20
m
g/
da
y
1
T
ra
ns
co
rt
ic
al
m
ot
or
ap
ha
si
a.
N
B
:r
ig
ht
fr
on
ta
ls
tr
ok
e
in
vo
lv
in
g
IF
G
.2
m
on
th
s
po
st
-s
tr
ok
e.
Im
pr
ov
ed
ve
rb
al
flu
en
cy
su
st
ai
ne
d
du
ri
ng
w
it
hd
ra
w
al
ph
as
es
—
th
is
co
ul
d
ha
ve
be
en
du
e
to
sp
on
ta
ne
ou
s
re
co
ve
ry
.
A
cl
in
ic
al
tr
ia
lo
f
br
om
oc
ri
pt
in
e
fo
r
tr
ea
tm
en
t
of
pr
im
ar
y
pr
og
re
ss
iv
e
ap
ha
si
a.
R
ee
d
(2
00
4)
.
R
an
do
m
is
ed
,d
ou
bl
e-
bl
in
de
d,
pl
ac
eb
o-
co
nt
ro
lle
d,
cr
os
so
ve
r.
B
ro
m
oc
ri
pt
in
e,
22
.5
m
g
pe
r
da
y
6
P
ri
m
ar
y
pr
og
re
ss
iv
e
ap
ha
si
a
(m
ea
n
ag
e
66
.8
ye
ar
s)
.
In
cr
ea
se
d
m
ea
n
le
ng
th
of
ut
te
ra
nc
e
bu
t
no
ef
fe
ct
on
flu
en
cy
or
na
m
in
g.
Su
gg
es
ts
a
sl
ow
in
g
of
de
cl
in
e
of
th
e
m
ot
or
ic
as
pe
ct
s
of
sp
ee
ch
.
A
ra
nd
om
is
ed
do
ub
le
bl
in
d
tr
ia
lo
f
br
om
oc
ri
pt
in
e
ef
fic
ac
y
in
no
n-
flu
en
t
ap
ha
si
a
af
te
r
st
ro
ke
.
A
sh
ta
ry
(2
00
6)
.
R
an
do
m
is
ed
,d
ou
bl
e-
bl
in
d,
pl
ac
eb
o-
co
nt
ro
lle
d.
B
ro
m
oc
ri
pt
in
e,
up
to
10
m
g/
da
y
38
N
on
-fl
ue
nt
ap
ha
si
c
pa
ti
en
ts
,P
er
si
an
sp
ea
ke
rs
,i
n
th
e
“a
cu
te
”
ph
as
e.
P
at
ie
nt
s
in
bo
th
gr
ou
ps
(p
la
ce
bo
an
d
br
om
oc
ri
pt
in
e)
im
pr
ov
ed
on
al
lm
ea
su
re
s.
N
o
si
gn
ifi
ca
nt
di
ff
er
en
ce
s
be
tw
ee
n
th
e
gr
ou
ps
.
N
ew
ap
pr
oa
ch
to
th
e
re
ha
bi
lit
at
io
n
of
po
st
-s
tr
ok
e
fo
ca
lc
og
ni
ti
ve
sy
nd
ro
m
e:
ef
fe
ct
of
le
vo
do
pa
co
m
bi
ne
d
w
it
h
sp
ee
ch
an
d
la
ng
ua
ge
th
er
ap
y
on
fu
nc
ti
on
al
re
co
ve
ry
fr
om
ap
ha
si
a.
Se
ni
ow
(2
00
9)
.
R
an
do
m
is
ed
,d
ou
bl
e-
bl
in
d,
pl
ac
eb
o-
co
nt
ro
lle
d.
L
-d
op
a,
10
0
m
g/
da
y.
U
se
d
in
a
ph
as
ic
m
an
ne
r
an
d
pa
ir
ed
w
it
h
SA
LT
39
A
ny
ap
ha
si
a
su
bt
yp
e.
A
cu
te
ph
as
e
(∼
5
w
ee
ks
po
st
-s
tr
ok
e)
.I
n-
pa
ti
en
ts
.
In
cr
ea
se
d
na
m
in
g
an
d
re
pe
ti
ti
on
on
L
-d
op
a
co
m
pa
re
d
w
it
h
pl
ac
eb
o.
F
ir
st
st
ud
y
to
at
te
m
pt
a
su
b-
gr
ou
p
an
al
ys
is
on
le
si
on
si
te
(p
at
ie
nt
s
w
it
h
“a
nt
er
io
r”
le
si
on
s
re
sp
on
de
d
be
tt
er
to
L
-d
op
a)
.
(C
on
ti
nu
ed
)
162 GILL AND LEFF
TA
B
LE
1
(C
o
n
ti
n
u
ed
)
T
it
le
,1
st
au
th
or
,y
ea
r
T
ri
al
ty
pe
D
ru
g
an
d
do
se
N
o.
P
ts
A
ph
as
ia
ty
pe
an
d
ch
ro
ni
ci
ty
M
ai
n
ou
tc
om
es
,c
om
m
en
ts
C
ro
ss
ov
er
tr
ia
lo
f
su
ba
cu
te
co
m
pu
te
ri
se
d
ap
ha
si
a
th
er
ap
y
fo
r
an
om
ia
w
it
h
th
e
ad
di
ti
on
of
ei
th
er
le
vo
do
pa
or
pl
ac
eb
o.
L
ee
m
an
,
L
ag
an
ar
o,
C
he
te
la
t-
M
ab
ill
ar
d,
an
d
Sc
hn
id
er
(2
01
1)
.
R
an
do
m
is
ed
,d
ou
bl
e-
bl
in
d,
pl
ac
eb
o-
co
nt
ro
lle
d,
cr
os
so
ve
r.
L
-d
op
a,
10
0
m
g/
da
y.
U
se
d
in
a
ph
as
ic
m
an
ne
r
an
d
pa
ir
ed
w
it
h
co
m
pu
te
ri
se
d
th
er
ap
y
an
d
SA
LT
.
12
2
=
B
ro
ca
’s
;2
=
W
er
ni
ck
e’
s;
6
=
an
om
ic
;
1=
co
nd
uc
ti
on
.A
cu
te
(∼
7.
5
w
ee
ks
)
Po
st
-s
tr
ok
e
(9
)
or
tr
au
m
at
ic
br
ai
n
in
ju
ry
(3
).
In
-p
at
ie
nt
s.
Si
gn
ifi
ca
nt
im
pr
ov
em
en
ts
on
th
e
tr
ea
te
d
it
em
s
fr
om
th
e
co
m
pu
te
ri
se
d
th
er
ap
y
ba
tt
er
y
bu
t
no
in
te
ra
ct
io
n
w
it
h
dr
ug
/
pl
ac
eb
o
bl
oc
k.
∗ A
lt
ho
ug
h
re
po
rt
ed
as
ra
nd
om
is
ed
(b
lo
ck
ra
nd
om
is
ed
),
al
l7
pa
ti
en
ts
w
er
e
ra
nd
om
is
ed
to
dr
ug
fir
st
th
en
pl
ac
eb
o.
Se
e
te
xt
fo
r
fu
rt
he
r
co
m
m
en
t.
#
H
ig
h
dr
op
-o
ut
ra
te
(5
4%
).
O
nl
y
5
co
m
pl
et
ed
th
e
st
ud
y.
DOPAMINERGIC THERAPY IN APHASIA 163
drug, the patient may have been affected by the inverted “U” shape curve described in
drug-based cognitive enhancement (Husain & Mehta, 2011).
In the same year, Sabe , Leiguarda, and Starkstein (1992) reported an open-label
trial in seven patients with mixed aphasia type and severity according to the Western
Aphasia Battery (WAB) (Kertesz, 1982): four moderate, three severe. The trial was
effectively an ABA design with language tests at eight consecutive time points (every
2 weeks) as the dose of bromocriptine was ramped up and then down (0, 15, 30, 45,
60, 30, 15, 0 mg). This sort of design is reasonable as any time effects or familiarity
with the language tests should be dissociable from drug effects when the dose ramps
down. In theory this type of study can be blinded (patients blinded to the dose), but it
looks like this was not the case. Conventional Speech and Language Therapy (SALT)
was administered as well. One has to interpret the results with caution as the numbers
were small, so inferences to the reference population (all aphasic patients of this type)
must necessarily be limited, but they did show convincing dose effects in the moderate
group’s lexical index scores (a measure of correct word production in a composite
picture description task), verbal fluency and pauses >3 seconds (a measure of speech
fluency). So some patients improved on a mixture of tests that could reflect improved
word retrieval, spoken fluency (motor) or non-specific effects such as attention. The
study was not placebo-controlled or blinded, so the authors followed it up with a
better designed study that was published three years later (Sabe et al., 1995). This also
had the same number of patients in the chronic phase but who were less variable in
terms of severity than the original study, all being in the moderate range on the WAB.
A similar escalation of bromocriptine as in the 1992 study (6 weeks on drug) was used,
but this time with no ramp-down, just a 3-week washout and thenmoving into the next
block (6 weeks on placebo). Language outcomemeasures were taken weekly. In theory,
this was a better designed study than the 1992 one; however, inexplicably, all patients
were allocated to the “bromocriptine first” group. The chances of this happening are
0.57 or 1/128, so either they were very unlucky or something went wrong with their
randomisation procedure. In small studies, it is a good idea to use block randomisation
to avoid this (Lachin, Matts, & Wei, 1988). While they did employ a crossover design,
the failure of random allocation of block order meant that time effects were conflated
with treatment effects although the study was negative, with no significant drug (or
time) effects found for any of the language outcome measures.
In the same issue of Neurology, Gupta et al. (1995) reported the findings of their
larger study with 20 patients at least 1 year post-stroke, median = 3 years (Gupta,
Mlcoch, Scolaro, & Moritz, 1995). This was a follow-on study from their 1992 paper
with two patients. They escalated the bromocriptine dose by 5 mg a week to 15 mg
which was given for 6 weeks followed by a 6-week washout. A crossover design
was employed with patients randomised to placebo first (n = 9) or bromocriptine
first (n = 11). SALT was prohibited during the trial so this was the first group
study to investigate dopaminergic effects independent of concomitant SALT. The trial
was well conducted; there were five evaluation periods, three at times when subjects
were drug/placebo-free so test-learning effects could be evaluated (and discounted).
Outcomes included language assessments (WAB, Boston naming tests and a transcrip-
tion of conversational speech) and cognitive assessments (Wechsler Memory Scale,
Raven’s Progressive Matrices and the Rey–Osterrieth Figure). There were no signifi-
cant effects (drug vs. placebo) on any of these outcome measures. The year 1995 was a
busy one and saw the publication of a third study that was also negative, although only
four patients took part (Ozeren, Sarica, Mavi, & Demirkiran, 1995). Bromocriptine
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was given initially at a dosage of 10 mg/day, and then 25 mg/day (no placebo).
The main outcome measure was a stratified version of the Aphasia Test for Turkish
Citizens where a speech sample was analysed and rated as either ‘‘A’’ (absence of
speech), ‘‘B’’ (utterances with polymorphic syllabic fragments and phonemic jargon)
or ‘‘C’’ (marked dysarthria and frequent stops within utterances). This outcome mea-
sure is almost certainly insensitive to the changes likely to be found with a drug
therapy. Bromocriptine was found to be ineffective.
A further case report of similar design but with superior outcome measures
was published as a book chapter (Berthier, 1999). This was an interesting case as
the patient, who suffered bi-hemispheric, subcortical strokes 7 months apart, had
Parkinsonian features as well as word-finding difficulties. After baseline assessment,
there was a clear improvement in the amount of speech produced (53 words in 120 sec-
onds of spoken picture description compared with six at baseline) with a more modest
improvement (57 vs. 50) in confrontation naming. Some other test scores remained
static suggesting some domain specificity, but with the lack of a placebo control, and
thus any attempt at blinding, any effects beyond the clearly impressive motoric ones,
are hard to interpret.
Gold, VanDam, and Silliman (2000) reported positive effects of bromocriptine
in a small (n = 4, no placebo) trial of ABBA design (Gold, VanDam, & Silliman,
2000). Drug therapy was not paired with SALT. They specifically targeted anomia
and used a bespoke anomia test with 420 items split into six lists of 70 matched items,
(parallel forms), which were computer-delivered. Reaction times were measured and
the authors also calculated a retrieval and storage quotient based on an analysis of
error type. They found that all four subjects improved their retrieval quotients on the
drug (with “large” effect sizes on Cohen’s d (0.74–3.4)). These dropped back towards
baseline once the drug was ramped down, in three out of the four subjects. If anything,
the effect on storage was in the other direction (worse on drug) with no consistent
effects on reaction times. There were no non-language tests.
Bragoni et al. (2000) used escalating doses of bromocriptine in 11 patients to report-
edly good effect, but there were several major flaws. The study was placebo-controlled
and tablet treatment was paired with SALT, but there was no block randomisation, so
all the patients received placebo first and then bromocriptine (each block = 60 days).
The authors claim the study was double-blinded, but it is not clear how the study
design was concealed from the assessing therapists. Side effects were common with
four patients dropping out because of these. Of the five that completed the study,
three had nausea despite domperidone cover. Drug studies with a high incidence of
side effects are likely to unblind subjects. Statistically significant improvements were
seen in several language measures, but in all these analyses, the data following the
drug and therapy block were compared with the baseline time point and not with
the data collected after the placebo and therapy block, e.g. the two biggest effects
were seen in reading aloud and dictation, but these improvements occurred after the
placebo plus SALT block (26% and 43%, respectively) with only marginal improve-
ment seen after the bromocriptine plus SALT block (29% and 47%, respectively).
In short, despite the claims of the authors, the results do not so much advance the
case of bromocriptine therapy as make a case for the effectiveness of SALT. Too great
a dose of bromocriptine was used as side effects were prohibitively high.
In 2001, Raymer et al. (2001) used bromocriptine on a single-subject with
transcortical motor aphasia due to a right frontal stroke. It was a no-placebo trial
with an ABABA design. There was no mention of concomitant SALT. The authors
included experimental (language) tasks that they predicted drug therapy would
improve, and a control task (gesture), where they predicted no improvement. Multiple
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tests were carried out to establish a baseline and the main outcome was the slope (rate
of improvement) in each of the four phases (the two drug blocks and the two follow-
ing washout periods). The patient’s ability to gesture did not improve significantly
across any block. The biggest effect was on verbal fluency with the authors arguing
that this was due to a bromocriptine as the rate of change on this measure was signifi-
cant for the first drug block but not the baseline block or either of the washout blocks.
However, the general trend in these control blocks was upwards and the appropriate
comparison would have been to directly compare the slopes of the drug blocks with
the control blocks, rather than comparing the slope of each block to the null (a flat
line). In short, the study produced no convincing evidence of a drug effect.
All of the studies discussed so far had been carried out with patients suffering from
post-stroke aphasia, but the next study was carried out on a group of six patients with
primary progressive aphasia (Reed, Johnson, Thompson, Weintraub, & Mesulam,
2004). It is a short report of less than 400 words, so details are slim, but it appears
to be a well-designed, placebo-controlled, double-blinded, crossover trial with three
main outcome measures: naming, word fluency and narrative language. The blocks
were ∼12 weeks long and while all the patients declined over this period, there was a
significant reduction in this decline for the bromocriptine block for the mean length
of utterance score (part of the narrative language score), suggesting a beneficial effect
of bromocriptine on the motoric aspects of speech.
The largest bromocriptine trial is the most recent one which included 38 patients
(Ashtary, Janghorbani, Chitsaz, Reisi, & Bahrami, 2006). This study recruited sub-
jects from a single site in Iran and was carried out in the acute phase. Subjects were
randomised by coin toss into the placebo or drug group. Coin-tossing is not a recom-
mended method for small trials as this can sometimes result in an allocation sequence
leading to groups that differ, by chance, quite substantially in size or in the occurrence
of prognostic factors (Altman & Bland, 1999); although that did not appear to be
the case with this study. A low dose of bromocriptine (10 mg per day) was used and
no side effects were reported. No mention was made whether concurrent SALT was
received by the patients. Performance on seven language tests and a control task (ges-
ture) was measured before and after therapy. The patients in both groups improved
on all eight outcome measures with no significant differences between the two groups;
that is, there were significant time effects but no significant drug vs. placebo effects.
The two most recent studies used L-dopa rather than bromocriptine. The first was
a well-designed, two-group study in 39 patients in the acute phase, on average 5 weeks
post-stroke. Tablet therapy was paired with SALT (Seniow, Litwin, Litwin, Lesniak, &
Czlonkowska, 2009). L-dopa was used in a phasic manner, that is, 100 mg (Madopar
125) was given 30 min prior to a SALT session which lasted for 45 min and occurred
five times a week for 3 weeks. Performance on 10 subtests of the Boston Diagnostic
Aphasia Examination was measured before and after therapy. As with the Ashtary
study, subjects in both groups improved significantly on all tests compared to baseline;
however, there was a significant group (L-dopa > placebo) effect on confrontation
naming and repetition. This seemed to be driven mainly by the patients with frontal
lesions (n = 12). Unlike previous studies, no attempt was made to limit recruitment
based on aphasia subtype.
The most recent study by Leeman et al. (2011) was also conducted in the acute
phase ∼7.5 weeks post-stroke and also used L-dopa in a phasic manner to augment
SALT. The SALT therapy was more complex as it comprised of standard therapy
in the afternoon, ∼1 hour a day, with additional computer-assisted therapy in the
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mornings. This was a programme that presented pictures to patients which they had
to name, but rather than name aloud, they had to type in the name of the item. The
authors examined item-specificity of the trained items across each block. The study
was a crossover one so each subject passed through drug and placebo blocks (block
duration only 2 weeks). There was an impressive effect of the computerised therapy
with naming accuracy improving on the trained list by 25% on average, but there was
no interaction with drug/placebo block. Although the therapy was supposed to be
timed with drug administration, it looks like some computerised sessions occurred in
the afternoon. Given that the half-life of the active drug (L-dopa with benserazide)
was 90 min, this may have led to under-dosing. The group was also small and mixed
(three had head injury rather than stroke) although the crossover design should have
helped reduce the effects of this somewhat. The authors’ conclusions to their study
pretty much mirror our general view that, “The type of substance, dose, time since
brain injury and the type and intensity of therapy and timing between drug admin-
istration and therapy are important factors that need more systematic exploration
(2011, p. 47)”.
DISCUSSION
Of the 15 studies discussed here, only seven reported a positive effect of dopaminergic
therapy. Two of these were randomised controlled trials, but the overall impression is
that the balance of evidence suggests no beneficial effect, on average, across the stud-
ies. A rather out-of-date Cochrane review dismissed all the evidence from any of the
dopaminergic therapy studies, although it was published prior to the more modern
and more rigorously controlled studies (Greener, Enderby, & Whurr, 2001). In terms
of the inferences one can make with frequentist statistics, positive studies carry more
weight than negative studies. As Fisher said, after a negative study, one can only “with-
hold judgment” (Dienes, 2011); but negative studies are harder to publish and one
can’t help but wonder if publication bias is at work here, especially for the smaller,
uncontrolled studies (Dwan et al., 2008).
If we put these concerns to one side for now and concentrate only on the positive
studies, can we discern any pattern of improvement that may give a clue as to how
and at what level (in terms of cognitive models) dopaminergic therapy may be work-
ing? Given that all of the studies focused either mainly or entirely on speech output,
we can perhaps use Levelt’s simplified model of speech production to try and assay
where the positive effects are manifest. Levelt divides speech output into four main
serial processes: concept generation, word-finding, motor planning and articulation
(Levelt, 1999). In terms of which aspects of speech or language function improved,
the following were found: naming/word-finding (5 studies); verbal fluency (which taps
into several components of Levelt’s model, 2 studies); motoric aspects of speech (rep-
etition, 3 studies). Of course, this type of analysis is dependent on how often the
individual measures were used and there is no accepted, standardised way of choos-
ing outcomes in aphasia research. Almost all of the studies measured naming ability.
There have been few studies in normal subjects that are relevant, but in a landmark
study, Knecht and colleagues investigated the effect of L-dopa in normal subjects on
novel word-learning in a randomised, placebo-controlled study (Knecht et al., 2004).
They used 100 mg of L-dopa in a phasic manner, timed with computer-based learn-
ing of new words (pseudowords) for pictures of familiar items. The L-dopa group
had significantly enhanced speed, overall success and long-term retention of novel
DOPAMINERGIC THERAPY IN APHASIA 167
word-learning than the placebo group, and they did so in a dose-dependent manner
(while all subjects in the L-dopa group received the same dose, in a clever twist, the
authors performed a subanalysis using a median split to assess this group by weight;
the lighter subjects did significantly better). They included appropriate tests to rule out
non-specific effects of motor performance, arousal, attention or response bias. The
evidence from this study suggests that task-dependent learning can be improved by
dopaminergic therapy, although the mechanism could be via the mesolimbic reward
system (Fiorillo, Tobler, & Schultz, 2003), prefrontal cortical circuitry underlying
working memory (Williams & Goldmanrakic, 1995) or via enhancing classical long-
term potentiation at the hippocampal–prefrontal synapses (Gurden, Takita, & Jay,
2000). Returning to the patient data, it is very difficult to say much about the lan-
guage specificity of these effects as few studies had a “control” outcome (two used
gesture) where one might expect no effect of therapy. No studies reported measures
of more basic cognitive components such as attention or vigilance which are likely to
impact on any task-specific measures, which is a shame as there is good evidence that
the dopaminergic system modulates these (Husain & Mehta, 2011); however, taken
together with the Knecht study, the positive evidence points towards either new encod-
ing (relearning) of word form information, or its enhanced retrieval as the most likely
mechanism of action of dopaminergic therapy.
Perhaps the biggest surprise is the lack of agents tried. Bromocriptine domi-
nates the literature, yet it has a poor side effect profile both in terms of short-term
administration (as shown in several of the trials reviewed here that tried to push the
dose to 30 mg/day and beyond) and in terms of longer-term risks of cardiorespiratory
fibrosis. This agent would be unlikely to find many takers in real-world clinical prac-
tice. L-dopa has more translational potential but its bioavailability means that it is best
suited for phasic use, perhaps paired with ongoing SALT. Both the trials using L-dopa
were in the acute phase, but there is no good reason to think it would not work in the
post-acute phase. Lastly, we were surprised that there are no studies with the newer
dopaminergic agents. A search of the US and EU clinical trial databases revealed
only a single ongoing trial of Tolcapone (a COMT inhibitor) in aphasic patients with
fronto-temporal dementia. Perhaps future studies will consider the non-ergot-derived
agonists or reuptake inhibitors such as methylphenidate.
All drug studies are resource-consuming and take a lot of effort, so what lessons
can be learnt from the studies reviewed here that might guide future work? Perhaps
firstly we should say that, given the effects and effect sizes of behavioural therapy,
future studies should pair dopaminergic drug therapy with behavioural therapy of
some sort; a view that others have endorsed (de Boissezon, Peran, de Boysson, &
Demonet, 2007). While we can probably draw a veil over bromocriptine, it would be
nice to see studies with newer agents or with L-dopa in the chronic phase. In terms of
study design, generally, double-blind, randomised, placebo-controlled trials are best.
Well-designed single-case or case-series studies are useful, but care should be taken
to control for placebo and time effects, so multiple baseline, ramp-up, ramp-down or
multiple alternating blocks (ABA, ABBA) should be considered (Hilliard, 1993). For
group studies, we prefer crossover designs as these deal effectively with inter-subject
variance, but if a more traditional two-group (or more) design is to be used, then
block randomisation and/or minimisation should be employed to reduce the risk of
the groups becoming unbalanced on key variables such as time since stroke or sever-
ity (Altman & Bland, 2005). Given the high incidence of side effects in some studies,
building in a de-escalation option in the study protocol will help keep some patients in
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the study side effect-free, albeit on a lower dose. This seems reasonable as higher doses
of cognitive enhancing drugs do not necessarily lead to better performance (Husain &
Mehta, 2011). Studying patients in the acute phase, when “natural” recovery curves
are at their steepest is always a challenge, but can be done using more innovative tech-
niques such as randomised N-of-1 designs (Edgington & Onghena, 2007). Husain and
colleagues used this in a study of the dopamine agonist rotigotine in acute, post-stroke
neglect to good effect (Gorgoraptis et al., 2012). Finally, what to measure? It is prob-
ably not a good idea for language outcomes to be fixed for all aphasia studies, as these
will need to be tailored to the impairments and disability profile of the participants,
which will necessarily vary from study to study. Standardised tests that are sensitive
to change, such as the Comprehensive Aphasia Battery (Swinburn, Porter, & Howard,
2004), are best. Non-language tests should also be included: probably a test of motor
function (as the main function of dopamine is on the motor system) and also a test
of attention. Lastly, patient-reported outcome measures should be used if possible
because if we are to hope for clinical translation to proceed from clinical trials, we will
need some evidence that patients or their carers find our interventions useful as well.
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